about
Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH Trials).Cardio-Oncology: Progress in Diagnosis and Treatment of Cardiac Dysfunction.Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction.Frequency of and Prognostic Significance of Cardiac Involvement at Presentation in Hereditary Transthyretin-Derived Amyloidosis and the Value of N-Terminal Pro-B-Type Natriuretic Peptide.Accumulation of 5-oxoproline in myocardial dysfunction and the protective effects of OPLAH.Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF.Predicting heart failure: one size does not fit all.Prevalence, clinical correlates, and outcomes of anaemia in multi-ethnic Asian patients with heart failure with reduced ejection fraction.Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry.Correction: Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry.Renal Function and Exercise Training in AmbulatoryHeart Failure Patients With a Reduced Ejection FractionHeart failure with preserved ejection fraction in AsiaFibrosis Marker Syndecan-1 and Outcome in Patients With Heart Failure With Reduced and Preserved Ejection FractionIdentifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection FractionHeart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-CHF studyHyperkalaemia: aetiology, epidemiology, and clinical significanceImpact of diabetes and sex in heart failure with reduced ejection fraction patients from the ASIAN-HF registry.Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response PatternsOPLAH ablation leads to accumulation of 5-oxoproline, oxidative stress, fibrosis, and elevated fillings pressures: a murine model for heart failure with a preserved ejection fractionNovel endotypes in heart failure: effects on guideline-directed medical therapyHeart Failure With Preserved Ejection Fraction in the YoungPrescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort studyPrescription patterns of anti-diabetic medications and clinical outcomes in Asian patients with heart failure and diabetes mellitus
P50
Q31141404-F43DBB4E-078A-4D86-9129-AC38BE398451Q39078275-1DE0951F-D970-4F43-9043-0025C6365193Q41165768-4C46ACE0-C8D4-4097-9CD5-705E78A86913Q47212930-C714553E-51D2-4DDD-89C9-22F90E56B5CDQ48339262-7CDC8EA8-7E41-4549-A48A-A7F3CA298701Q48741948-91821439-310C-4E15-93CF-0241CF4FA11FQ50048467-5845A3C9-A595-4A57-82EC-E4194E3EC9C3Q52617061-ADFA4F6D-6741-45CF-B92A-998DF5F9A58FQ52627988-38168730-1D4D-48D4-941C-DB08C7CF74A7Q55240052-54EFFE87-7BEF-4118-830D-993925AE6629Q57074649-25B4F44F-4941-44F7-BEE5-3B8039A4F8E3Q57213752-AEB63E84-D15F-4DD1-BD0D-997707871A77Q57315206-B23A7E4C-B0EA-426E-AFDD-70DF55184C26Q57911312-80C60807-92B9-4AE4-93DB-384AD5025BC2Q58587336-F3C2963E-E8FC-4760-B887-050B1491EAD5Q64100073-7C5EFF41-F239-406B-88DD-1295BF7B0ABEQ64973417-43847F4E-DEC2-4EFE-B513-B487C797EA31Q89574690-5CEF886C-FD1E-4611-9292-EF7A59C6261DQ90387207-2AACE5FC-0B7A-404C-983D-955D886CA036Q90509209-97FE5B60-B486-4C6D-995E-7FB13B958A4BQ90632459-EBF0AD80-82D8-436B-A2D0-F8E370A97CE1Q90925000-B9A5DDE3-1F4F-4A36-9A62-F65BE2CB70D5Q91593010-9452175B-4D4A-40D8-80A4-7E39A7D44AB8
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jasper Tromp
@ast
Jasper Tromp
@en
Jasper Tromp
@es
Jasper Tromp
@nl
type
label
Jasper Tromp
@ast
Jasper Tromp
@en
Jasper Tromp
@es
Jasper Tromp
@nl
prefLabel
Jasper Tromp
@ast
Jasper Tromp
@en
Jasper Tromp
@es
Jasper Tromp
@nl
P106
P31
P496
0000-0001-6043-0713